A Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma


Full Title

Safety and Immunological Effects of Ablative Radiotherapy followed by Pembrolizumab in Patients with Advanced Adrenocortical Carcinoma


Researchers want to see if combining radiation therapy and immunotherapy is safe and works well for treating advanced adrenocortical cancer. The people in this study have adrenocortical cancer that spread to other parts of the body, including the liver.

If you join this study, you will first have a type of radiation called intensity-modulated radiation therapy (IMRT). IMRT directs radiation to cancer cells from different angles by changing the radiation beam into multiple smaller beams.

Then you will get pembrolizumab. This drug takes the brakes off the immune response, allowing your immune system to find and kill cancer cells. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have adrenocortical carcinoma that has spread, including to your liver.
  • Have recovered from the serious side effects of prior therapies.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Nitya Raj’s office at 646-888-4849.




Phase II (phase 2)

Disease Status

Newly Diagnosed & Relapsed/Refractory




ClinicalTrials.gov ID